| scholarly article | Q13442814 |
| P50 | author | John P. Curtin | Q38801361 |
| Franco Muggia | Q30512486 | ||
| P2093 | author name string | Leonard Liebes | |
| Paul Christos | |||
| Joseph A Sparano | |||
| Helen X Chen | |||
| Stephanie V Blank | |||
| Carolyn D Runowicz | |||
| Noah Goldman | |||
| P2860 | cites work | Targeted inhibition of transient activation of the EGFR-mediated cell survival pathway enhances paclitaxel-induced ovarian cancer cell death. | Q38320166 |
| Improved survival for fallopian tube cancer: a comparison of clinical characteristics and outcome for primary fallopian tube and ovarian cancer. | Q40028239 | ||
| Improved survival time: what can survival cure models tell us about population-based survival improvements in late-stage colorectal, ovarian, and testicular cancer? | Q40105863 | ||
| Enhanced sensitivity to the HER1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib hydrochloride in chemotherapy-resistant tumor cell lines. | Q40451017 | ||
| Determinants of tumor response and survival with erlotinib in patients with non--small-cell lung cancer | Q40489484 | ||
| Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer | Q40673230 | ||
| Final survival and safety results from a multicenter, open-label, phase 3b trial of erlotinib in patients with advanced nonsmall cell lung cancer | Q42653421 | ||
| Phase II study of gefitinib in patients with relapsed or persistent ovarian or primary peritoneal carcinoma and evaluation of epidermal growth factor receptor mutations and immunohistochemical expression: a Gynecologic Oncology Group Study | Q46630310 | ||
| Efficacy and safety of erlotinib HCl, an epidermal growth factor receptor (HER1/EGFR) tyrosine kinase inhibitor, in patients with advanced ovarian carcinoma: results from a phase II multicenter study | Q46712990 | ||
| Effect of Epidermal Growth Factor Receptor Expression Level on Survival in Patients with Epithelial Ovarian Cancer | Q57904896 | ||
| Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: the Tarceva Lung Cancer Investigation Trial | Q80178480 | ||
| Epithelial growth factor receptor status in primary and recurrent ovarian cancer | Q82917858 | ||
| Gene amplification, mutation, and protein expression of EGFR and mutations of ERBB2 in serous ovarian carcinoma | Q83139511 | ||
| Global cancer statistics, 2002 | Q27860562 | ||
| Erlotinib in previously treated non-small-cell lung cancer | Q29547546 | ||
| Cancer statistics, 2009 | Q29547625 | ||
| Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer | Q29616236 | ||
| Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: a Phase III Trial of the Gynecologic Cancer Intergroup | Q30436714 | ||
| Gefitinib: a review of its use in the management of advanced non-small-cell lung cancer | Q33207883 | ||
| Comparison of RNA amplification methods and chip platforms for microarray analysis of samples processed by laser capture microdissection | Q33286603 | ||
| Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: a gynecologic oncology group study | Q33331105 | ||
| Review of the comparative pharmacology and clinical activity of cisplatin and carboplatin | Q33718099 | ||
| TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. | Q34436986 | ||
| Cutaneous adverse effects with HER1/EGFR-targeted agents: is there a silver lining? | Q36211421 | ||
| A review of erlotinib and its clinical use. | Q36376408 | ||
| Panitumumab: in the treatment of metastatic colorectal cancer | Q36651665 | ||
| Role of surgery in ovarian carcinoma | Q36873048 | ||
| Cetuximab: a review of its use in squamous cell carcinoma of the head and neck and metastatic colorectal cancer | Q37011976 | ||
| Phase II trial of single agent cetuximab in patients with persistent or recurrent epithelial ovarian or primary peritoneal carcinoma with the potential for dose escalation to rash | Q37340624 | ||
| P433 | issue | 3 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | ovarian cancer | Q172341 |
| carboplatin | Q415588 | ||
| erlotinib | Q418369 | ||
| paclitaxel | Q423762 | ||
| P304 | page(s) | 451-456 | |
| P577 | publication date | 2010-09-15 | |
| P1433 | published in | Gynecologic Oncology | Q5625182 |
| P1476 | title | Erlotinib added to carboplatin and paclitaxel as first-line treatment of ovarian cancer: a phase II study based on surgical reassessment | |
| P478 | volume | 119 |
| Q33835932 | A loop of cancer-stroma-cancer interaction promotes peritoneal metastasis of ovarian cancer via TNFα-TGFα-EGFR |
| Q83389063 | A phase II trial of Erlotinib in combination with gemcitabine and cisplatin in advanced pancreatic cancer |
| Q38631373 | An overview of tyrosine kinase inhibitors for the treatment of epithelial ovarian cancer. |
| Q36321894 | Anti-epidermal growth factor receptor (EGFR) antibodies overcome resistance of ovarian cancer cells to targeted therapy and natural cytotoxicity |
| Q38965047 | BRCA1-IRIS inactivation sensitizes ovarian tumors to cisplatin |
| Q37637147 | Characterization of ovarian clear cell carcinoma using target drug-based molecular biomarkers: implications for personalized cancer therapy |
| Q37671783 | Comprehensive profiling of EGFR/HER receptors for personalized treatment of gynecologic cancers |
| Q35767493 | Contributions of the Epidermal Growth Factor Receptor to Acquisition of Platinum Resistance in Ovarian Cancer Cells |
| Q33829859 | Dacomitinib, a pan-inhibitor of ErbB receptors, suppresses growth and invasive capacity of chemoresistant ovarian carcinoma cells |
| Q90224747 | EGFR-Specific Tyrosine Kinase Inhibitor Modifies NK Cell-Mediated Antitumoral Activity against Ovarian Cancer Cells |
| Q26863231 | EGFR/HER-targeted therapeutics in ovarian cancer |
| Q36322658 | Epidermal Growth Factor Receptor (EGFR) Pathway Biomarkers in the Randomized Phase III Trial of Erlotinib Versus Observation in Ovarian Cancer Patients with No Evidence of Disease Progression after First-Line Platinum-Based Chemotherapy |
| Q24236143 | Epidermal growth factor receptor blockers for the treatment of ovarian cancer |
| Q57456685 | Epidermal growth factor receptor blockers for the treatment of ovarian cancer |
| Q91603678 | Human epidermal growth factor receptor targeted inhibitors for the treatment of ovarian cancer |
| Q52717288 | Integrative kinome profiling identifies mTORC1/2 inhibition as treatment strategy in ovarian clear cell carcinoma. |
| Q90231859 | Kinase Inhibitors and Ovarian Cancer |
| Q37185385 | Network analysis identifies an HSP90-central hub susceptible in ovarian cancer |
| Q47424260 | Novel antiangiogenic therapies in ovarian cancer |
| Q35659945 | Ovarian cancer: opportunity for targeted therapy |
| Q36880902 | Profile of erlotinib and its potential in the treatment of advanced ovarian carcinoma |
| Q55491850 | Small Molecules Identified from a Quantitative Drug Combinational Screen Resensitize Cisplatin's Response in Drug-Resistant Ovarian Cancer Cells. |
| Q35619189 | Synergistic anti-tumor effect of combined inhibition of EGFR and JAK/STAT3 pathways in human ovarian cancer |
| Q98164379 | Targeted therapies in gynecological cancers: a comprehensive review of clinical evidence |
| Q38118388 | Targeting tyrosine-kinases in ovarian cancer |
| Q30248645 | The Emerging Role of Tyrosine Kinase Inhibitors in Ovarian Cancer Treatment: A Systematic Review |
| Q38144166 | The potential of sunitinib as a therapy in ovarian cancer |
| Q50345037 | The rise of genomic profiling in ovarian cancer |
| Q34806737 | The therapeutic potential of targeting the EGFR family in epithelial ovarian cancer |
| Q38248418 | Treatment of ovarian cancer beyond chemotherapy: are we hitting the target? |
Search more.